Asherman syndrome is recognized by uterine adhesions or fibrosis caused by endometrial injury. This can result in dysmenorrhea, infertility, and pregnancy loss. Platelet-rich fibrin (PRF) contains a large number of platelets and is a source of growth factors, which have been proven to stimulate wound healing, proliferation, and migration of cells. Therefore, PRF is a potential biomaterial for treating endometrial damage. This research was carried out on mice to estimate the effects of gel PRF (gPRF) on damaged endometrium by mechanical force using a 25-gauge needle. The murine model of Asherman syndrome was divided into three groups under any circumstances, including the sham-operated (control) group, the negative control group (PBS group), and the treatment group (gPRF group). The results revealed that one dose of gPRF (20 μL/horn) increased the number of uterine glands, the thickness of the endometrium, and the outcome of pregnancy in the mice’s uterus (P < 0.05). To use gPRF in clinical treatments to recover endometrial damage, this study provides a scientific foundation for that possibility.
Key words: platelet-rich fibrin, damaged endometrium, intrauterine, Asherman syndrome, regenerative medicine
|
